PainChek Ltd (AU:PCK) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PainChek Ltd is advancing its US market entry strategy with the successful completion of a validation study for its Adult App, paving the way for a November 2024 FDA De Novo submission. The positive results align with previous studies and could lead to PainChek becoming the first FDA-cleared pain assessment tool for aged care residents in the US. This potential clearance is expected to significantly expand PainChek’s market reach in the US, offering a substantial revenue opportunity.
For further insights into AU:PCK stock, check out TipRanks’ Stock Analysis page.